NASDAQ:OPTN - OptiNose Stock Price, Forecast & News

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

OptiNose Inc (NASDAQ:OPTN) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.69) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.69). The company had revenue of $12.40 million for the quarter, compared to the consensus estimate of $8.56 million. OptiNose had a negative return on equity of 137.60% and a negative net margin of 419.37%. View OptiNose's Earnings History.

OptiNose is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for OptiNose.

6 brokerages have issued 12-month price objectives for OptiNose's stock. Their forecasts range from $20.00 to $29.00. On average, they anticipate OptiNose's share price to reach $24.83 in the next year. This suggests a possible upside of 232.9% from the stock's current price. View Analyst Price Targets for OptiNose.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose.

News headlines about OPTN stock have been trending neutral on Saturday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. OptiNose earned a daily sentiment score of 0.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for OptiNose.

OptiNose saw a drop in short interest in January. As of January 31st, there was short interest totalling 7,980,000 shares, a drop of 10.6% from the January 15th total of 8,930,000 shares. Based on an average trading volume of 270,900 shares, the short-interest ratio is currently 29.5 days. Currently, 36.5% of the shares of the stock are short sold. View OptiNose's Current Options Chain.

Some companies that are related to OptiNose include Supernus Pharmaceuticals (SUPN), Revance Therapeutics (RVNC), Akebia Therapeutics (AKBA), Rocket Pharmaceuticals (RCKT), Athenex (ATNX), Odonate Therapeutics (ODT), NextCure (NXTC), Phibro Animal Health (PAHC), Enanta Pharmaceuticals (ENTA), Opko Health (OPK), Phathom Pharmaceuticals (PHAT), Portola Pharmaceuticals (PTLA), Karyopharm Therapeutics (KPTI), Kiniksa Pharmaceuticals (KNSA) and Dermira (DERM).

Based on aggregate information from My MarketBeat watchlists, some companies that other OptiNose investors own include Idera Pharmaceuticals (IDRA), Proteostasis Therapeutics (PTI), Clearside Biomedical (CLSD), Syndax Pharmaceuticals (SNDX), Arcos Dorados (ARCO), Coherus Biosciences (CHRS), Resonant (RESN), OrganiGram (OGI), SVB Financial Group (SIVB) and Stemline Therapeutics (STML).

(OPTN) raised $101 million in an initial public offering (IPO) on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO.

OptiNose's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (16.54%), Thrivent Financial for Lutherans (4.09%), Rice Hall James & Associates LLC (3.08%), Franklin Resources Inc. (3.01%), Tamarack Advisers LP (2.53%) and Farallon Capital Management LLC (2.16%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose.

OPTN stock was sold by a variety of institutional investors in the last quarter, including Wildcat Capital Management LLC, Rice Hall James & Associates LLC, Goldman Sachs Group Inc., Credit Suisse AG and UBS Group AG. Company insiders that have sold OptiNose company stock in the last year include Avista Capital Partners Ii Gp, and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.

OPTN stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, FMR LLC, Franklin Resources Inc., Tamarack Advisers LP, Kornitzer Capital Management Inc. KS, Thrivent Financial for Lutherans, Geode Capital Management LLC and Perceptive Advisors LLC. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OPTN stock can currently be purchased for approximately $7.46.

OptiNose has a market capitalization of $310.19 million and generates $7.07 million in revenue each year. The company earns $-106,660,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. OptiNose employs 102 workers across the globe.View Additional Information About OptiNose.

The official website for OptiNose is http://www.optinose.com/.

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]